Highlights
• Radiopharm shares rose 5% to AUD 0.021 on 8 April 2026 following clinical trial progress
• DSMC recommends advancement to Cohort 3 at 130mCi dose level
• Phase 1 ‘HEAT’ trial progressing in HER2-positive advanced solid tumors
• Trial escalation supported by favourable safety profile observed to date
• Company remains on track to complete Phase 1 dose escalation by end of 2026

Radiopharm Theranostics Ltd (ASX:RAD) shares gained 5% to AUD 0.021 on 8 April 2026, with the market responding to a key clinical milestone in the development of its oncology asset, 177Lu-RAD202. The share price move follows confirmation that the company has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to progress its Phase 1 trial to the next dose level.

Clinical Progress Drives Momentum

The company announced that its Phase 1 ‘HEAT’ clinical trial evaluating RAD202 in patients with HER2-positive advanced solid tumors has successfully advanced to Cohort 3. The DSMC has recommended escalation to a higher dose level of 130mCi after reviewing safety data from earlier cohorts.

The DSMC plays a critical role in clinical trials, independently assessing patient safety, monitoring adverse events, and determining whether studies can safely proceed. The positive recommendation indicates that the trial has demonstrated a safety profile supportive of continued dose escalation.

This progression marks an important step in evaluating the therapeutic potential of RAD202, particularly in targeting cancers with HER2 overexpression.

Dose Escalation Reflects Favourable Safety Profile

The advancement from Cohort 2 to Cohort 3 follows earlier dosing at 75mCi, with the trial now moving to a higher intensity level. The ability to escalate dosing is typically dependent on safety outcomes, and the decision to proceed suggests that RAD202 has been well tolerated by patients in earlier stages.

Management highlighted that the pace of progression in the study reflects both strong execution and encouraging safety observations. The company expects to continue advancing through dose levels, with the goal of completing Phase 1 dose escalation by the end of 2026.

The ongoing study is being conducted across multiple clinical centres in Australia, supporting patient recruitment and trial execution.

Targeting HER2 in Advanced Cancers

RAD202 is designed to target Human Epidermal Growth Factor Receptor 2 (HER2), a protein commonly overexpressed in several types of cancer, including breast cancer and other solid tumors.

HER2 is a well-established target in oncology, with therapies directed at this receptor already forming part of standard treatment in certain cancers. Radiopharm’s approach combines targeting capability with radiotherapeutic delivery, aiming to provide a novel treatment option for patients with advanced disease.

In earlier diagnostic studies involving HER2-positive breast cancer patients, RAD202 demonstrated proof-of-concept along with favourable biodistribution and safety characteristics, supporting its progression into therapeutic development.

Building a Broad Oncology Pipeline

Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for both diagnostic and therapeutic applications in oncology.

The company’s pipeline spans multiple technology platforms, including peptides, small molecules, and monoclonal antibodies, targeting a range of solid tumor cancers such as lung, breast, prostate, and brain cancers.

In addition to the RAD202 program, Radiopharm is advancing several other clinical assets, including one Phase 2 study and multiple Phase 1 trials, reflecting a diversified development strategy.

The continued progress of RAD202 adds to the company’s broader pipeline momentum and highlights its focus on addressing areas of high unmet medical need.

Execution and Timeline Remain on Track

The company indicated that, based on current progress, it remains on track to complete the Phase 1 dose escalation component of the RAD202 trial by the end of 2026.

This timeline suggests a structured and steady advancement through clinical milestones, which is critical for maintaining development momentum and progressing toward later-stage trials.

The ability to move efficiently through early-stage clinical development is often a key factor in investor confidence, particularly in the biotechnology sector where timelines and regulatory milestones play a central role in valuation.

What This Means for Investors?

The advancement of RAD202 into a higher dose cohort represents a meaningful clinical milestone for Radiopharm. The DSMC’s positive recommendation reinforces confidence in the safety profile observed so far and supports continued progression of the trial.

Today’s share price increase appears to reflect investor optimism around the program’s momentum and its potential within the competitive oncology landscape. As the trial continues, further updates on safety, dosing, and early efficacy signals will be closely monitored.

With multiple clinical programs underway and a focus on innovative radiopharmaceutical therapies, Radiopharm remains positioned as a development-stage company with ongoing clinical catalysts.